Systemic Amyloidosis Therapeutic Market is Anticipated to Witness High Growth Owing to Increasing Drug Approvals



Systemic amyloidosis refers to the extracellular deposition of insoluble amyloid fibrils in various organs and tissues. These amyloid fibrils disrupt normal tissue architecture and organ functioning. The diseases associated with systemic amyloidosis include AL amyloidosis, AA amyloidosis and hereditary ATTR amyloidosis. There are various therapeutic products in clinical trials and pipeline for the treatment of systemic amyloidosis. The treatment landscape includes small molecules as well as monoclonal antibodies.


The global Systemic Amyloidosis Therapeutic Market is estimated to be valued at US$ 6.19 billion in 2024 and is expected to exhibit a CAGR of 7.9% over the forecast period of 2024-2031.

Key Takeaways
Key players operating in the systemic amyloidosis therapeutic market are AstraZeneca, Attralus, Ionis Pharmaceuticals, Prothena Biosciences, Alexion Pharmaceuticals.
The key opportunities in the market include rising awareness about the diseases, introduction of new treatment options and strong pipeline of drugs. The market players are exploring opportunities in developing regions like Asia Pacific and Latin America through collaborations and licensing agreements.

Market drivers and restrain
The key drivers for the growth of systemic amyloidosis therapeutic market include increasing drug approvals and launches. For instance, in 2019, the FDA approved tafamidis (Vyndaqel and Vyndamax) developed by Pfizer for the treatment of ATTR amyloidosis. The drug witnessed high adoption rate owing to its effectiveness.
However, lack of understanding about rare nature of diseases like amyloidosis remains a major challenge. Also, high cost of therapies poses difficulty for healthcare systems of developing nations to provide access to treatment.


Segment Analysis
The systemic amyloidosis therapeutic market covers different types of amyloidosis such as light-chain (AL) amyloidosis, hereditary amyloidosis, and wild-type transthyretin amyloidosis. Light-chain (AL) amyloidosis accounts for majority of the cases and holds the largest share in the market currently. It is caused due to abnormal production of light chains of antibodies or immunoglobulins by plasma cells. Wild-type transthyretin amyloidosis is also a dominating sub segment due to increasing levels of wild-type ATTR amyloidosis cases being identified.

Global Analysis
Geographically, North America is expected to dominate the market during the forecast period. Increasing awareness about amyloidosis and presence of key market players are factors driving the market in the region. The Asia Pacific region is projected to be the fastest growing regional market by 2031 due to rising prevalence of light-chain amyloidosis, increasing healthcare expenditure, and expanding healthcare infrastructure.

Get more insights on this topic : https://justpaste.it/702t2

What Are The Key Data Covered In This Systemic Amyloidosis Therapeutic  Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Systemic Amyloidosis Therapeutic 's growth between 2024 and 2031.

:- Accurate calculation of the size of the Systemic Amyloidosis Therapeutic  and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Systemic Amyloidosis Therapeutic  Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Systemic Amyloidosis Therapeutic  vendors

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it

Comments

Post a Comment

Popular posts from this blog

Laser Projection Market is to Witness High Growth Owing to Advancements in RGB Laser Projection Technology

Image
  The laser projection market involves the usage of laser diodes and phosphor wheels to project images instead of traditional light bulbs and rotating color wheels. Laser projection technology offers a variety of benefits over conventional projection including high brightness levels, long lifespan, high resolutions, and high contrast ratios. Laser projectors are increasingly being used for entertainment and commercial applications such as cinemas, digital signage, and conferences & seminars. The demand for   Laser Projection Market is driven by the superior image quality, higher resolutions and brighter images they provide compared to conventional projectors. The laser projection market is estimated to be valued at   USD 17.52 Bn in 2024   and is expected to reach   USD 56.28 Bn by 2031,  growing at a compound annual growth rate  (CAGR) of 18.1% from 2024 to 2031.  Key Takeaways Key players: Key players operating in the laser projection...
Read more

AL Amyloidosis Diagnostics is to Witness High Growth due to Advancements in Molecular Diagnostics and Flow Cytometry

Image
AL amyloidosis, also called primary (AL) amyloidosis, is a plasma cell disorder characterized by the buildup of abnormal protein deposits known as amyloid in tissues and organs. AL amyloidosis can affect the heart, kidneys, liver, nervous system, and digestive system. Early and precise diagnosis of AL Amyloidosis Diagnostics Market is very important for effective treatment and management of the disease. The AL amyloidosis diagnostic market is estimated to be valued at  USD 1.068 billion in 2024   and is expected to reach   USD 1.693 billion by 2031 , growing at a compound annual growth rate   (CAGR) of 6.8% from 2024 to 2031. Key Takeaways Key players operating in the AL amyloidosis diagnostics are Siemens Healthineers, Abbott Laboratories, IMMUNOConcepts, PrognostiX, Ark Diagnostics. The key opportunities in the AL amyloidosis diagnostics market include development of minimally invasive diagnostic techniques, adoption of PET imaging for diagnosis, advanceme...
Read more

Navigating the Stuttering Treatment Market: Top Solutions for Effective Speech Therapy

Image
The stuttering treatment market involves speech therapy techniques that help reduce or eliminate stuttering or stammering symptoms. Stuttering or stammering occurs when the flow of speech is disrupted by involuntary blocking, repetition, or prolongation of certain sounds. Such involuntary disruptions create difficulties in expressing thoughts fluently which can negatively impact an individual's self-confidence and social interactions. The need for effective Stuttering Market treatment solutions is rising due to the availability of advanced methods such as modified fluency shaping techniques, delayed auditory feedback devices, and self-therapy programs. The Global Stuttering Market is estimated to be valued at   USD 51.5 million in 2024   and is expected to reach   USD 150.1 million by 2031 , growing at a compound annual growth rate   (CAGR) of 11.3% from 2024 to 2031. Key Takeaways Key players operating in the stuttering treatment market are Johnson & Johns...
Read more